Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

Similar articles for PubMed (Select 9086161)

1.

High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.

de Jong MD, Vella S, Carr A, Boucher CA, Imrie A, French M, Hoy J, Sorice S, Pauluzzi S, Chiodo F, Weverling GJ, van der Ende ME, Frissen PJ, Weigel HM, Kauffmann RH, Lange JM, Yoon R, Moroni M, Hoenderdos E, Leitz G, Cooper DA, Hall D, Reiss P.

J Infect Dis. 1997 Apr;175(4):966-70.

2.

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, et al.

J Infect Dis. 1995 Mar;171(3):537-45.

PMID:
7533197
3.

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141-51.

PMID:
7530585
4.

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.

de Jong MD, Loewenthal M, Boucher CA, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R, et al.

J Infect Dis. 1994 Jun;169(6):1346-50.

PMID:
8195615
5.

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

Ann Intern Med. 1997 Jun 15;126(12):929-38.

PMID:
9182469
6.

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.

Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, Lamson M, Cort S, Sullivan JL.

J Infect Dis. 1996 Oct;174(4):713-21.

8.

Experience with nevirapine in previously treated HIV-1-infected individuals.

Wit FW; Dutch HIV-treating physicians.

Antivir Ther. 2000 Dec;5(4):257-66.

PMID:
11142620
9.

Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.

Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.

Antivir Ther. 1997 Jul;2(3):175-83.

PMID:
11322272
10.

Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.

de Jong MD, Schuurman R, Lange JM, Boucher CA.

Antivir Ther. 1996 Jan;1(1):33-41.

PMID:
11322257
11.

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.

Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL.

J Infect Dis. 2002 Jul 15;186(2):181-8. Epub 2002 Jun 26.

12.

Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.

Relimpio F, Rey C, Pineda JA, Leal M, Caruz A, Sánchez-Quijano A, Lissen E.

Antivir Ther. 1997 Apr;2(2):99-104.

PMID:
11322281
13.

Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.

Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI.

Retrovirology. 2006 Dec 21;3:97.

14.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
15.

Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.

de Jong MD, de Boer RJ, de Wolf F, Foudraine NA, Boucher CA, Goudsmit J, Lange JM.

AIDS. 1997 Sep;11(11):F79-84.

PMID:
9302437
16.

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36.

PMID:
11464141
17.

Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.

Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.

Antivir Ther. 1996 Dec;1(4):211-9.

PMID:
11324823
18.

API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.

Gupta SB, Pujari SN, Joshi SR, Patel AK; AIDS Society of India Guidelines Development Committee.

J Assoc Physicians India. 2006 Jan;54:57-74. Review.

PMID:
16649742
19.

Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.

Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD.

J Infect Dis. 2000 Feb;181(2):522-31.

20.

Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.

Re MC, Bon I, Monari P, Borderi M, Gibellini D, Schiavone P, Vitone F, Chiodo F, La Placa M.

Int J Antimicrob Agents. 2003 Oct;22(4):388-94.

PMID:
14522102
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk